Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue; Offers FY25 EPS Guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $47.04 -0.28%
EPS Growth %: +10.7%
Financial Fact:
Research and development expenses: 232M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +10.7%
Financial Fact:
Research and development expenses: 232M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.70, $0.04 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.56 billion versus the consensus estimate of $4.41 billion.
GUIDANCE:
Boston Scientific sees FY2025 EPS of $2.80-$2.87, versus the consensus of $2.81.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
- Pakistan's Sharif: Confirm That A Final, Agreed Text Reached
- Village Super Market (VLGEA) Declares $0.25 Quarterly Dividend; 2.4% Yield
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
